Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development 

FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive this designation with the potential to become the first in the category to advance to a pivotal trial in RA, pending FDA feedback expected in 1H 2026

Read more at globenewswire.com